Oncology News

Oncology

sponsor

Your Unread Messages

Hello, Suzanne Dixon
Manage E-mail  |  Logout
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Kasamon YL et al. – ASCT with rituximab can produce durable remissions on follow–up out to 10 years. Major infections do not appear to be significantly increased or to be predicted by immune monitoring.



Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address